射频消融术联合EGFR-TKI靶向治疗非小细胞肺癌的疗效观察  

作　　者：黄精益 姚征[2] 周霞[2] 高铖铖 

机构地区：[1]浙江省医疗健康集团杭州医院,310022 [2]浙江省肿瘤医院,310022 [3]西湖大学医学院附属杭州市第一人民医院,310006

出　　处：《浙江临床医学》2024年第9期1345-1347,共3页Zhejiang Clinical Medical Journal

摘　　要：目的探讨射频消融术(RFA)联合表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗小细胞肺癌(NSCLC)患者的临床疗效及安全性。方法收集2022年1月至2023年12月在浙江省肿瘤医院接受治疗且具有完整资料的NSCLC患者120例,根据随机数字表法,分为观察组(RFA联合EGFR-TKI靶向治疗)与对照组(RFA联合GP化疗)各60例。分别于治疗前及治疗后进行血清肿瘤标志物(CEA、NSE、CYFRA21-1)、免疫功能(CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+))检测,对患者进行疗效分级,计算总有效率,观察患者不良反应。结果肿瘤标志物水平两组治疗后较治疗前均有所降低,差异有统计学意义(P<0.05),观察组与对照组比较差异有统计学意义(P<0.05);治疗前CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)差异无统计学意义(P>0.05),治疗后观察组CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)较对照组高,差异有统计学意义(P<0.05);两组治疗前后差异有统计学意义(P<0.05);观察组完全缓解、部分缓解总例数较对照组多,总有效率差异有统计学意义(P<0.05);随访安全性,两组不良反应差异无统计学意义(P>0.05)。结论RFA联合EGFR-TKI靶向治疗,能够改善NSCLC患者肿瘤标志物水平,提升免疫功能,该方法疗效可靠,可予以推广。Objective To explore the clinical efficacy and safety of radio frequency ablation(RFA)combined with EGFR-tyrosine kinase inhibitor(EGFR-TKI)targeted therapy in patients with non-small cell lung cancer(NSCLC).Methods A total of 120 NSCLC patients treated in Zhejiang Cancer Hospital from January 2022 to December 2023 with complete data were collected.The patients were divided into two groups according to the random number table method,the observation group(RFA combined with EGFR-TKI targeted therapy)and the control group(RFA combined with GP chemotherapy),with 60 cases in each group.Serum tumor markers(CEA,NSE,CYFRA21-1)and immune function markers(CD_(4)^(+),CD_(8)^(+),CD_(4)^(+)/CD_(8)^(+))were measured before and after treatment,respectively.The therapeutic effects were graded,the total effective rate was calculated,and the types and numbers of adverse reactions in patients were monitored.Results The levels of tumor markers were significantly reduced after treatment compared with before treatment,with statistically significant differences(P<0.05).The differences in the observation group before and after treatment were larger than those in the control group,with statistically significant differences(P<0.05).The inter-group comparison showed no statistically significant differences in CD_(4)^(+),CD_(8)^(+),and CD_(4)^(+)/CD_(8)^(+)+before treatment(P>0.05),while after treatment,the observation group had higher levels of CD4 and CD_(4)^(+)/CD_(8)^(+)than the control group(P<0.05).The intra-group comparison showed statistically significant differences before and after treatment(P<0.05).The therapeutic effect grading results showed that the observation group had more cases of complete and partial remission than the control group,and the difference in the total effective rate was statistically significant(P<0.05).Adverse reactions were monitored in both groups,and the inter-group differences were no statistical significance(P>0.05).Conclusion The combination of RFA with EGFR-TKI targeted therapy can improve the levels

关 键 词：射频消融术 非小细胞肺癌 EGFR-TKI靶向治疗 免疫功能 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]